Downregulation of Nodal inhibits metastatic progression in retinoblastoma.
Invasion
Nodal
Proliferation
Retinoblastoma
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
26 08 2019
26 08 2019
Historique:
received:
28
06
2019
accepted:
07
08
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
31
7
2020
Statut:
epublish
Résumé
Retinoblastoma is the most common intraocular malignancy in children. We previously found that the ACVR1C/SMAD2 pathway is significantly upregulated in invasive retinoblastoma samples from patients. Here we studied the role of an ACVR1C ligand, Nodal, in regulating growth and metastatic dissemination in retinoblastoma. Inhibition of Nodal using multiple short hairpin (shRNAs) in WERI Rb1 and Y79 retinoblastoma cell cultures reduced growth by more than 90%, as determined by CCK-8 growth assay. Proliferation was also significantly inhibited, as found by Ki67 assay. These effects were paralleled by inhibition in the phosphorylation of the downstream effector SMAD2, as well as induction of apoptosis, as we observed more than three-fold increase in the percentage of cells positive for cleaved-caspase-3 or expressing cleaved-PARP1. Importantly, we found that downregulation of Nodal potently suppressed invasion in vitro, by 50 to 80%, as determined by transwell invasion assay (p = 0.02). Using an orthotopic model of retinoblastoma in zebrafish, we found 34% reduction in the ability of the cells to disseminate outside the eye, when Nodal was knocked down by shRNA (p = 0.0003). These data suggest that Nodal plays an important role in promoting growth, proliferation and invasion in retinoblastoma, and can be considered a new therapeutic target for both primary tumor growth and metastatic progression.
Identifiants
pubmed: 31451106
doi: 10.1186/s40478-019-0785-4
pii: 10.1186/s40478-019-0785-4
pmc: PMC6709548
doi:
Substances chimiques
NODAL protein, human
0
Nodal Protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Subventions
Organisme : NEI NIH HHS
ID : P30 EY001765
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA229919
Pays : United States
Références
Oncogene. 2010 May 27;29(21):3110-23
pubmed: 20383200
Biofactors. 2019 May;45(3):355-363
pubmed: 30985990
Proc Natl Acad Sci U S A. 2017 May 2;114(18):E3719-E3728
pubmed: 28416692
Cancer Res. 1977 Apr;37(4):1003-10
pubmed: 844036
J Natl Cancer Inst. 1974 Aug;53(2):347-60
pubmed: 4135597
Pediatr Blood Cancer. 2011 Mar;56(3):341-8
pubmed: 21225909
Expert Rev Dermatol. 2009;4(1):67-78
pubmed: 19885369
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
Am J Cancer Res. 2015 May 15;5(6):2098-112
pubmed: 26269769
Int J Mol Med. 2017 Oct;40(4):1172-1184
pubmed: 28848998
Oncotarget. 2016 Oct 25;7(43):70028-70044
pubmed: 27661116
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34
pubmed: 18334633
Prostate. 2011 Aug 1;71(11):1198-209
pubmed: 21656830
Int J Ophthalmol. 2018 Dec 18;11(12):2011-2016
pubmed: 30588438
Mol Cancer Ther. 2017 May;16(5):787-792
pubmed: 28468864
Oncogene. 2018 Mar;37(12):1551-1560
pubmed: 29321667
Development. 2005 Mar;132(6):1273-82
pubmed: 15703277
Am J Cancer Res. 2016 Nov 01;6(11):2431-2447
pubmed: 27904762
J Cancer. 2019 Feb 26;10(6):1511-1519
pubmed: 31031861
Semin Cancer Biol. 2014 Dec;29:40-50
pubmed: 25073112
Onco Targets Ther. 2018 Oct 05;11:6589-6597
pubmed: 30323631
Oncotarget. 2015 Oct 27;6(33):34071-86
pubmed: 26460952
Br J Ophthalmol. 2010 Nov;94(11):1432-6
pubmed: 20733021
PLoS One. 2015 Jan 20;10(1):e0114954
pubmed: 25603319
J Pediatr Ophthalmol Strabismus. 2018 May 1;55(3):182-188
pubmed: 29257183
Oncotarget. 2015 Feb 20;6(5):3165-77
pubmed: 25638158
Am J Ophthalmol. 2006 Aug;142(2):310-5
pubmed: 16876514
Invest Ophthalmol Vis Sci. 2013 Jan 09;54(1):295-306
pubmed: 23211831
Nat Commun. 2019 Mar 6;10(1):1089
pubmed: 30842446
Br J Ophthalmol. 2009 Sep;93(9):1129-31
pubmed: 19704035
FEBS Lett. 2012 Jul 4;586(14):1833
pubmed: 22651913
Mol Cell Biol. 2004 Nov;24(21):9383-9
pubmed: 15485907
Turk J Ophthalmol. 2015 Dec;45(6):259-267
pubmed: 27800245
Cancer Lett. 2013 Jun 1;333(1):66-75
pubmed: 23348697
Oncogene. 2019 Mar;38(12):2056-2075
pubmed: 30401983
Stem Cell Reports. 2015 Oct 13;5(4):532-45
pubmed: 26388287
J Clin Invest. 2012 Feb;122(2):425-34
pubmed: 22293180